Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.